ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2021
Drug-Free, Nonsurgical Reduction of Intraocular Pressure for Four Months after Suprachoroidal Injection of Hyaluronic Acid Hydrogel.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 48 citations in OpenAlex.
- Microneedle technology in the treatment of ocular diseases: Advances and applications.Asian journal of pharmaceutical sciences · 2026Review
- Sustained intraocular pressure lowering from suprachoroidal injection of a latanoprost lipid nanoparticle delivery system in the rabbit.Frontiers in medicine · 2026Article
- Drug-free hyaluronic acid-microneedle with unexpected inhibition activity on benzalkonium chloride-induced corneal inflammation and stromal scarring.Materials today. Bio · 2025Article
- Advances in adhesive hydrogels applied for ophthalmology: An overview focused on the treatment.Theranostics · 2025Review
- Revolutionizing Eye Care: Exploring the Potential of Microneedle Drug Delivery.Pharmaceutics · 2024Review
- IOP Reduction in Nonhuman Primates by Microneedle Injection of Drug-Free Hydrogel to Expand the Suprachoroidal Space.Translational vision science & technology · 2024Article
- Ophthalmic Tethered Gold Yarnball-Mediated Retained Drug Delivery for Eye Fundus Disease Treatment.Small science · 2024Article
- What's New in Ocular Drug Delivery: Advances in Suprachoroidal Injection since 2023.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Next generation therapeutics for retinal neurodegenerative diseases.Journal of controlled release : official journal of the Controlled Release Society · 2024Review
- Smart molecules in ophthalmology: Hydrogels as responsive systems for ophthalmic applications.Smart molecules : open access · 2024Review
- Hydrogels in Ophthalmology: Novel Strategies for Overcoming Therapeutic Challenges.Materials (Basel, Switzerland) · 2023Review
- Segmental Unconventional Outflow in Mouse Eyes.Investigative ophthalmology & visual science · 2023Article
- Suprachoroidal Injection: A Novel Approach for Targeted Drug Delivery.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Breaking Barriers in Eye Treatment: Polymeric Nano-Based Drug-Delivery System for Anterior Segment Diseases and Glaucoma.Polymers · 2023Review
- Suprachoroidal Delivery in Rats and Guinea Pigs Using a High-Precision Microneedle Injector.Translational vision science & technology · 2023Article
- Microneedle-based interstitial fluid extraction for drug analysis: Advances, challenges, and prospects.Journal of pharmaceutical analysis · 2023Review
- Eyedrop-based macromolecular ophthalmic drug delivery for ocular fundus disease treatment.Science advances · 2023Article
- Intravitreal Injectable Hydrogels for Sustained Drug Delivery in Glaucoma Treatment and Therapy.Polymers · 2022Review
- Collecting and deactivating TGF-β1 hydrogel for anti-scarring therapy in post-glaucoma filtration surgery.Materials today. Bio · 2022Article
- Suprachoroidal Delivery of Small Molecules, Nanoparticles, Gene and Cell Therapies for Ocular Diseases.Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
Abstract
Glaucoma is the leading cause of irreversible blindness. Current treatments use drugs or surgery to reduce intraocular pressure (IOP). In this study, a drug-free, nonsurgical method is developed that lowers IOP for 4 months without requiring daily patient adherence. The approach involves expanding the suprachoroidal space (SCS) of the eye with an in situ-forming hydrogel injected using a microneedle. This study tests the hypothesis that SCS expansion increases the drainage of aqueous humor from the eye via the unconventional pathway, which thereby lowers IOP. SCS injection of a commercial hyaluronic acid (HA) hydrogel reduces the IOP of normotensive rabbits for more than 1 month and an optimized HA hydrogel formulation enables IOP reduction for 4 months. Safety assessment by clinical ophthalmic examinations indicate the treatment is well tolerated. Histopathology shows minor hemorrhage and fibrosis at the site of injection. Further analysis by ultrasound biomicroscopy demonstrates a strong correlation of IOP reduction with SCS expansion. Outflow facility measurements show no difference in pressure-dependent outflow by the conventional pathway between treated and untreated eyes, supporting the hypothesis. In conclusion, SCS expansion with an in situ-forming hydrogel can enable extended IOP reduction for treating ocular hypertension and glaucoma without drugs or surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.